Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practicePneumococcal vaccinesgeneral practicevaccination coverageagedprimary health carecomorbidityIn Australia, pneumococcal vaccine is provided free to all adults aged ≥65years and Indigenous people aged 15–65years, ...
Keywords and Medical Subject Headings were related to our population (i.e.; older adults over the age of 65) and the intervention (i.e., pneumococcal vaccine). Databases were searched from January 2015 until April 2020. The cut-off date was selected based on preliminary searches of the ...
Darwin, Australia state that the researchers' conclusions exceed the evidence presented. They caution that there should be no change in vaccine policy in countries that recommend PPV to prevent invasive pneumococcal disease.
The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia for childhood vaccinations, there has been little detailed quantitative analysis on the potential impact of the timeliness of vaccinations in older adults. The... ...
What are the features of the newly registered 15-valent pneumococcal conjugate vaccine (PCV15)? There are over 100 serotypes of pneumococcus, of which serotype 3 is the biggest threat. Regardless of age, in recent years, most severe and hospitalised cases of pneumococcal infection are caused by...
Retrospective impact analysis and cost-effectiveness of the pneumococcal conjugate vaccine infant program in Australia. Infect Dis Ther. 2021;10(1):507–20. Article PubMed PubMed Central Google Scholar Pfizer. Pfizer Press Release. Pfizer Announces Positive Top-Line Results from Phase 3 Study of ...
Our study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis. Trial registration Australia and New Zealand Clinical Trials Registry (ANZCTR) number: ACTRN12612000034831.
Streptococcus pneumoniae is a bacterium that lives in the nose of many people. It's often harmless but can cause multiple problems. Some are potentially serious.
3. Over a century on, serotype 1 prevails as one of the most prevalent invasive serotypes, with a high incidence of disease reported globally, throughout Europe4,5,6,7,8,9, South America10, Asia11,12, Australia13,14and particularly dominant in sub-Saharan Africa where it is responsible ...
Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999: 553–607 Google Scholar McGeer A, Landry L, Goldenberg E, et al. Population-based surveillance for invasive pneumococcal infections in Toronto, Canada: implications for prevention [...